KPW
DNLI icon

Kore Private Wealth’s Denali Therapeutics DNLI Stock Holding History

Kore Private Wealth’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-500
Closed -$12K – 479
2020
Q2 		$12K Hold
500
– – ﹤0.01% 745
2020
Q1 		$9K Hold
500
– – ﹤0.01% 704
2019
Q4 		$9K Buy
+500
New +$8.32K ﹤0.01% 759
2019
Q2 		– Sell
-1,000
Closed -$23K – 379
2019
Q1 		$23K Buy
+1,000
New +$20.9K 0.01% 493

Other funds holding DNLI

CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Kore Private Wealth's DNLI Position: Q3 2020 in Review

Kore Private Wealth sold out of Denali Therapeutics (DNLI) in Q3 2020, closing a stake of 500 shares — an estimated $12K sold.

Kore Private Wealth first reported a position in DNLI in Q1 2019 and held it in 4 quarters. The position peaked at $23K in Q1 2019. 170 funds tracked by Wall St. Rank hold DNLI as of Q3 2020.

  • Kore Private Wealth reported no remaining Denali Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Kore Private Wealth sold 500 Denali Therapeutics shares in Q3 2020, an estimated $12K.
  • Kore Private Wealth first reported a position in Denali Therapeutics in Q1 2019 and held it in 4 quarters.
  • Kore Private Wealth's Denali Therapeutics position peaked at $23K in Q1 2019.
  • 170 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2020.

Based on Kore Private Wealth's 13F filing for Q3 2020, filed 13 Nov 2020.